Regulus Therapeutics Inc. (NASDAQ:RGLS) will be posting its quarterly earnings results after the market closes on Tuesday, August 1st. Analysts expect Regulus Therapeutics to post earnings of ($0.31) per share for the quarter.

Regulus Therapeutics Inc. (RGLS) traded down 6.72% during trading on Thursday, hitting $1.11. 1,388,682 shares of the company’s stock were exchanged. The firm’s market cap is $59.03 million. The company’s 50-day moving average price is $1.04 and its 200 day moving average price is $1.40. Regulus Therapeutics Inc. has a 12-month low of $0.86 and a 12-month high of $3.93.

ILLEGAL ACTIVITY WARNING: “Regulus Therapeutics Inc. (NASDAQ:RGLS) to Release Earnings on Tuesday” was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/07/27/regulus-therapeutics-inc-nasdaqrgls-to-release-earnings-on-tuesday.html.

In related news, CFO Daniel R. Chevallard purchased 54,945 shares of the business’s stock in a transaction that occurred on Tuesday, July 25th. The stock was bought at an average price of $0.91 per share, with a total value of $49,999.95. Following the acquisition, the chief financial officer now owns 59,415 shares in the company, valued at $54,067.65. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Joseph P. Hagan purchased 219,780 shares of the business’s stock in a transaction that occurred on Tuesday, July 25th. The stock was bought at an average cost of $0.91 per share, with a total value of $199,999.80. Following the acquisition, the insider now owns 241,297 shares in the company, valued at approximately $219,580.27. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 549,450 shares of company stock valued at $500,000. Insiders own 4.80% of the company’s stock.

Several research firms have recently weighed in on RGLS. Wedbush reaffirmed an “outperform” rating and set a $6.00 target price on shares of Regulus Therapeutics in a report on Wednesday, March 29th. ValuEngine lowered shares of Regulus Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. BMO Capital Markets reaffirmed a “hold” rating on shares of Regulus Therapeutics in a report on Monday, May 15th. Chardan Capital cut their target price on shares of Regulus Therapeutics from $5.00 to $2.50 and set a “buy” rating for the company in a report on Tuesday, June 13th. Finally, Zacks Investment Research raised shares of Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.00 target price for the company in a report on Wednesday, July 12th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the stock. Regulus Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $3.92.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Earnings History for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.